Participated · Equity · Feb 2025

BEKhealth, based in Research Triangle Park, NC, provides an AI-powered chart abstraction and patient-matching platform that extracts structured and unstructured data from electronic medical records (EMRs). The technology integrates EHR data to optimize population feasibility and rapidly identify clinically qualified participants for clinical research. Its platform supports organizations conducting clinical trials, observational research, and real-world evidence generation by improving protocol design and participant identification. The company announced customer growth in 2024 and now counts clients such as Avacare Clinical Research Network, Biopharma Informatics, Chemidox, Elixia Health, Javara, Om Research and others. BEKhealth raised $4M in funding and intends to use the proceeds to continue expanding its customer base and product offering. The company highlights its focus on expanding commercial adoption and enhancing its AI-driven capabilities to better serve research sponsors and sites. BEKHealth offers an AI-powered clinical research software platform that ingests and processes both structured and unstructured EMR data to drive feasibility assessments, site selection, precision patient matching, and care coordination. Its machine learning models combine more than 400 unique medical libraries and 70,000 research protocols with an interoperable clinical data model to power automated, daily identification of protocol-eligible patients. The platform is positioned to accelerate patient enrollment, cut timelines, and improve outcomes for sites and CROs while addressing cumbersome workflows and data access challenges. BEKHealth says its tools are increasingly in demand amid a more virtual healthcare environment and growing use of analytics in clinical research. The company is privately held, venture-backed, and based in Connecticut, and plans to use new funding to grow its team and expand availability and adoption of its platform.

Led · Series A · Oct 2023

Korio offers a randomization and trial supply management (RTSM) platform designed to improve clinical trial quality, speed, and reliability. The platform enables users to adapt to protocol changes, surface audit trails and cross-portfolio data, and flag integration disruptions. When customers need guidance, Korio provides access to knowledgeable and responsive RTSM experts. Led by CEO Ryan Keane and based in Doylestown, PA, the company emphasizes expert client services and support. Korio intends to use the Series A proceeds to accelerate global expansion with a focus on its client services and support team. Financial terms of the round were not disclosed; the round was led by BIP Ventures with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners, and other strategic investors. Korio offers a clinical trial software platform focused on Randomization & Trial Supply Management (RTSM) that streamlines processes and delivers predictable outcomes within shorter timeframes. The platform integrates insights and expertise from industry subject‑matter experts to challenge complex, manual workflows common among RTSM providers. Led by CEO Ryan Keane, the company emphasizes a technology‑first approach to replace manual processes. Korio intends to use its recent funding to support expansion and to bolster its team. The company said the capital will help it respond to increasing demand from life sciences and clinical research organizations. The articles do not disclose additional operating metrics or past financing details.

Led · Seed · Oct 2023

Atalan Tech provides an advanced machine-learning platform that analyzes data from healthcare providers’ existing systems to identify clinician and nurse burnout and predict turnover risks. Its early-warning system can forecast, prevent, and help budget for clinician staff turnover up to approximately 12 months in advance. The platform is aimed at accelerating early prediction and prevention of healthcare worker burnout and turnover. The company is led by Co-Founder and CEO Tiffany Chan and Co-founder and Chief Well-being Economist Sisi Hu. Atalan plans to use new funding to accelerate research and development and to expand its team of interdisciplinary scientists. It will also ramp up sales and marketing efforts to grow adoption among healthcare providers.

Participated · Equity · Jan 2023

Censinet offers Censinet RiskOps, a cloud-based, HIPAA-secure risk exchange that automates third-party and enterprise risk-management workflows for providers, payers, and vendors. Its platform includes a Digital Risk Catalog of over 34,000 vendors and products, automated corrective action plans, real-time portfolio management, and Board-ready reporting. The company reports close to 40 customers, 100% ARR growth year-over-year through Q3 2022, and says it has never lost a customer. Censinet recently launched a Healthcare Cybersecurity Benchmarking Study co-sponsored by the American Hospital Association and KLAS Research. The new funding is earmarked for sales and marketing, product development, and customer success to expand the customer base, drive ACV expansion via new product modules, and enter adjacent markets and verticals. Censinet is based in Boston, MA. Censinet offers the Censinet Platform, described as the first third-party risk management platform built by and for healthcare providers to manage vendor threats to patient care. The platform includes One-click Assessment capabilities and a Digital Vendor Catalog that the company says reduce vendor risk assessment time from weeks to seconds, automate workflows, and provide continuous real-time vendor risk insights. Censinet maintains an advisory board of C-level executives from top-tier healthcare providers and vendors who served as design partners during product development. The company announced the launch of the Censinet Platform in April 2019 and emphasizes a security-first approach targeted at healthcare CIOs and CISOs. Censinet intends to use recent funding to expand the platform’s vendor risk management capabilities, scale its go-to-market team, and accelerate adoption by healthcare providers and their vendors. Censinet is led by CEO and Founder Ed Gaudet and is based in Boston, MA.

Participated · Equity · Jun 2021

Ride Health is a Flatiron District–based medical transit management company whose app enables healthcare providers to book and coordinate rides for patients going to and from appointments. The software integrates with ride-hailing services like Uber and Lyft and tailors transportation based on riders’ medical records and personal preferences. Current customers include health systems such as NYC Health + Hospitals and Memorial Sloan Kettering, as well as programs serving elderly individuals and people with intellectual or developmental disabilities whose trips are paid for by Medicare, Medicaid or grant funding. In 2024, the firm plugged into Unite Us, allowing providers on that social-care referral platform to schedule Medicaid-covered rides under a $7.5 billion 1115 waiver pilot. Ride Health also offers tools for providers that own their own vehicles and drivers and plans to grow this fleet-management line. Founder Imran Cronk describes the addressable market as “enormous,” though the company has not disclosed revenue or user figures. The business has now secured an additional $15 million through extensions of its earlier Series A round, building on the $10 million Series A it raised in 2021.